Recent progress in work on PGD2 antagonists for drugs targeting allergic diseases

Current Pharmaceutical Design

Volumn 10, Issue 28, 2004, Pages 3533-3538

  Mitsumori, Susumu ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

BWA868C; CRTH2; Eosinophil; Indometahcin; PGD2; Ramatroban; S 5751

Indexed keywords

1,2,3,4 TETRAHYDROCARBAZOLE DERIVATIVE; 13,14 DIHYDRO 15 OXOPROSTAGLANDIN D2; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; ANTIALLERGIC AGENT; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON TH2 CELL RECEPTOR; DOMITROBAN; INDOLE DERIVATIVE; INDOMETACIN; PROSTAGLANDIN D2; PROSTAGLANDIN D2 DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; RAMATROBAN; S 5751; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; MAST CELL; METABOLITE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH2 CELL;

ANIMALS; ANTI-ALLERGIC AGENTS; HUMANS; HYPERSENSITIVITY; LIGANDS; PROSTAGLANDIN D2; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 5744239544     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382864     Document Type: Review

References (42)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
2. Bahram R, Johan S, Kiyo N, Charlotta L, Göran S, Maria A, et al. Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents. J Med Chem 1993; 36: 243-248.
3. 2α Analogues: Potential Antiglaucoma Agens. Bioorg Med Chem Lett 1993; 3: 241-244.
4. Robert CN, Michael HT, Helmut V. Prostacyclin-Analogs. Med Res Rev 1985; 5: 1-53.
5. John FP, Karel FB, David K, Ruth P, Martin JW. Prostaglandins and Congeners. Synthesis of Simplified Prostaglandins. Inhibition of Gastric Acid Secretion by 2-(ω-carboxyalkyl -3-alkylcycloalkanones. J Med Chem 1975; 18: 359-362.
6. Ferreira SH, Moncada S, Vane JR. Indomethacin and Aspirin Abolish Prostaglandin Release from the Spleen. Nature New Biol 1971; 231: 237-239.
7. Miller TA. Protective Effects of Prostaglandins against Gastric Mucosal Damage: Current Knowledge and Proposed Mechanisms. Am J Physiol 1983; 245: G601-G623.
8. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982; 129: 1627-1631.
9. 2 in rat and human skin. Br J Pharmacol 1976; 56: 229-233.
10. Doyle WJ, Boehm S, Skoner DP. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol 1990; 86: 924-935.
11. 2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur Respir J 1995; 8: 411-415.
12. 2. Invest Ophthalmol Vis Sci 1990; 31: 138-146.
13. 2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol 1989; 67: 959-962.
14. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995; 270: 18910-18916.
15. 2 Receptor Antagonists. J Med Chem 1997; 40: 3504-3507.
16. Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa S, Kakudo S, et al. Prevention of Allergic Inflammation by a Novel Prostaglandin Receptor Antagonist, S-5751. J Pharmacol Exp Ther 2001; 298: 411-419.
17. 2 Receptor Antagonists. 1. Bicyclo[2.2.1] heptane Derivatives. J Med Chem 2003; 46: 2436-2445.
18. 2 Receptor Antagonists. 2. 6, 6-Dimethylbicyclo[3.1.1]heptane Derivatives. J Med Chem 2003; 46: 2446-2455.
19. 2 as a Mediator of Allergic Asthma. Science 2000; 287: 2013-2017.
20. Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y. Pronounced Eosinophilic Lung Inflammation and Th2 Cytokine Release in Human Lipocalin-Type Prostaglandin D Synthase Transgenic Mice. J Immunol 2002; 168: 443-449.
21. Caldwell AG, Harris CJ, Stepney R, Whittaker N. Hydantoin Prostaglandin Analogues, Potent and Selective Inhibitors of Platelet Aggregation. J Chem Soc Chem Commun 1979; 13: 561-562.
22. Barraclough P, Brockwell M, Caldwell AG, Demaine DA, Harris CJ, Richard King W, et al. Synthesis and Inhibitory Activity on Platelet Aggregation of 13′-Aza and Other ω-Chain Modified BW245C Analogues. Arch Pharm (Weinheim) 1994; 327: 307-317.
23. Barraclough P, Bolofo ML, Giles H, Gillam J, Harris CJ, Kelly MG, et al. Synthesis of Hexahydrocyclopentimidazol-2-(1H -one Derivatives Displaying Selective DP-Receptor Agonist Properties. Bioorg Med Chem 1996; 4: 81-90.
24. Caldwell AG. Japan Patent Kokai 1984; 59-157072.
25. Caldwell AG. European Patent 1984; 126849 A1.
26. Crider JY, Griffin BW, Sharif NA. Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists. Br J Pharmacol 1999; 127: 204-210.
27. 3H]-BWA868C, a DP receptor-selective antagonist radioligand. Br J Pharmacol 2000; 131: 1025-1038.
28. Sharif NA, Crider JY, Xu SX, Williams GW. Affinities, Selectivities, Potencies, and Intrinsic Activities of Natural and Synthetic Prostanoids Using Endogenous Receptors: Focus on DP Class Prostanoids. J Pharmacol Exp Ther 2000; 293: 321-328.
29. Merck Frosst Canada & Co. The use of DP receptor antagonists to treat allergic rhinitis. Expert Opin Ther Patents 2002; 12: 597-599.
30. Merck Frosst Canada & Co. European Patent 1989; 00300676.
31. Torisu K, Hasegawa T, Kobayashi K, Nambu F. 2003; WO03/022813 A1.
32. Torisu K, Iwahashi M, Kobayashi K, Nambu F. 2003; WO03/022814 A1.
33. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001; 98: 1942-1948.
34. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 1999; 459(2):195-199.
35. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193(2): 255-261.
36. Johnston SL, Bardin PG, Harrison J, Ritter W, Joubert JR, Holgate ST. The effects of an oral thromboxane TP receptor antagonist BAY u3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma and relationship to plasma drug concentrations. Br J Clin Pharmacol 1992; 34: 402-408.
37. 2-and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1992; 89: 1119-1126.
38. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. An Orally Bioavailable Small Molecule Antagonist of CRTH2, Ramatroban (BAY u3405), Inhibits Prostaglandin D2-Induced Eosinophil Migration in vitro. J Pharmacol Exp Ther 2003; 305: 347-352.
39. 2 Receptor, CRTH2. J Immunol 2002; 168: 981-985.
40. Hawkey CJ, Skelly MM. Gastrointestinal safety of selective COX-2 inhibitors. Curr Pharm Design 2002; 8(12): 1077-89.
41. Uings I, McKinnon M. Development of IL-5 receptor antagonists. Curr Pharm Design 2002; 8(20): 1837-44.
42. Ventura MT, Muratore L, Calogiuri GF, Dagnello M, Buquicchio R, Nicoletti A, et al. Allergic and pseudoallergic reactions induced by glucocorticoids: a review. Curr Pharm Design 2003; 9(24): 1956-64.